PROMO!
First order? Get 10% OFF with this code: 1storder
Vilon is a synthetic dipeptide composed of lysine and glutamic acid residues (Lys-Glu), studied for its effects on cellular signaling and biochemical processes.
Vilon is a synthetic dipeptide made up of the amino acids L-lysine and L-glutamic acid and is usually denoted as Lys-Glu (KE) or H-Lys-Glu-OH; according to PubChem the compound is known as L-lysyl-L-glutamic acid and includes Vilon as one of its synonyms.
Since Vilon consists of only two amino acid residues, it is considerably smaller and less complex than ordinary polypeptides and proteins. The fact that its sequence and stereochemistry are well defined means that it is appropriate for use in controlled studies relating to short-peptide chemistry, molecular interactions, and cellular research models.
Experimental studies have looked into Vilon in a variety of in vitro and animal research setups, with some of the investigations focusing on cellular regulation and biochemical responses. Yet, a great deal of the existing Vilon literature comes from a rather narrow research tradition, and therefore the findings of individual experiments should not be taken as proving the existence of a general molecular mechanism.
Vilon can be evaluated with regard to its research materials by using the analytical methods usually applied to short peptides, with a particular focus on its chemical identity, purity, stereochemistry, and the analytical records associated with each batch.
Vilon is a synthetic dipeptide made up of two L-amino acid units, namely L-lysine and L-glutamic acid; its specific sequence is Lys-Glu (KE), and this may also be written as H-Lys-Glu-OH. The compound is also known as L-lysyl-L-glutamic acid.
The peptide has a molecular formula of C₁₁H₂₁N₃O₅ and an average molecular weight of about 275.30 g/mol; since it is a two-residue peptide, Vilon is considerably simpler in structure than longer peptides and proteins and lacks disulfide bonds, glycosylation, and a complex tertiary protein structure.
Because it has ionizable functional groups derived from the side chain of lysine, the side chain of glutamic acid, and the peptide termini, its charge depends on the pH; for the purpose of characterizing the research material the important molecular identifiers are its L-Lys-L-Glu sequence, its stereochemistry, its molecular formula and its expected molecular mass.
These characteristics can be evaluated using standard short-peptide analytical methods, including chromatographic and mass-spectrometric techniques, together with batch-specific documentation.
Vilon (Lys-Glu) has been investigated primarily in experimental models examining cellular signaling and regulation of gene expression. Unlike peptides whose mechanisms are defined by binding to a well-characterized cell-surface receptor, the molecular mechanism proposed for Vilon remains less clearly established and should be described as an area of continuing investigation.
Gene-Expression Research
Studies carried out in vitro have looked into whether Lys-Glu can affect transcriptional activity in lymphocyte models. In one experiment that had been published, it was found that there were changes in the expression of the interleukin-2 (IL-2) gene in mouse spleen lymphocytes after they had been exposed to Lys-Glu. The authors suggested a number of possible mechanisms which were related to transcription, but these stayed as hypotheses and were not confirmed as indicating a specific molecular target.
Cellular Signal-Transduction Research
Vilon has also been investigated in isolated mouse thymocytes with regard to the sphingomyelin signalling pathway. Experiments measured thymocyte proliferation and sphingomyelinase activity, giving biochemical indicators for examining whether the dipeptide takes part in the signalling processes associated with these cells.
Proposed Molecular Regulation
A broader hypothesis within the short-peptide literature proposes that small peptides such as Lys-Glu may participate in the regulation of DNA accessibility, chromatin organization or transcription-associated processes. For Vilon specifically, however, a definitive molecular binding target and complete signaling mechanism have not been independently established. These proposed mechanisms should therefore be distinguished from experimentally confirmed receptor pharmacology.
Overall, Vilon provides a defined dipeptide for laboratory investigation of gene-expression changes, cellular signaling, and short-peptide molecular regulation. Much of the published evidence is preclinical and originates from a relatively concentrated research lineage, so findings should be interpreted within the specific experimental models in which they were obtained.
This summary reflects findings reported in published preclinical and in vitro research. The original studies supporting this information are listed in the references.
Vilon (Lys-Glu) has been investigated in cell-based models examining gene-expression regulation. Published in-vitro studies have measured changes in interleukin-2 (IL-2) mRNA expression in mouse splenocytes and lymphocytes following experimental exposure to Lys-Glu.
Experimental studies using isolated mouse thymocytes have examined Vilon in relation to cellular signal-transduction pathways. One area of investigation has involved sphingomyelinase activity and the sphingomyelin signaling pathway, providing biochemical endpoints for studying short-peptide interactions with thymocyte signaling processes.
Vilon has likewise been the subject of laboratory studies which looked at chromatin structure and transcriptional accessibility. Research carried out on cultured lymphocytes has examined the changes in heterochromatin organization and in the nucleolar organizer regions after exposure to a peptide. However, these findings are specific to the model in question and cannot be taken as demonstrating a general molecular mechanism for Vilon.
Experiments carried out using thymocytes and thymic epithelial cells have looked at the argyrophilic proteins linked to the nucleolar organizer regions. These models offer a basis for investigating the possible connections between exposure to Vilon, the organisation of ribosomes, and the processes of cellular protein synthesis.
Vilon has on many occasions been studied together with some other short synthetic peptides, such as Epithalon and Cortagen. By carrying out comparative experiments, researchers are able to see if peptides which have different primary structures lead to distinct responses in the same cellular or biochemical system.
Most of the available evidence is experimental and preclinical, and much of the published work on Vilon comes from a relatively concentrated research literature. These findings should be interpreted within the specific laboratory models in which they were obtained and should not be considered evidence of therapeutic effects or outcomes in humans.
Analytical verification of Vilon (Lys-Glu) can include assessment of the identity and purity of the supplied dipeptide. Chromatographic purity can be assessed by evaluating the main peptide peak and detectable impurities using high-performance liquid chromatography. HPLC with UV detection can assess chromatographic purity.
Liquid chromatography–mass spectrometry (LC-MS) or another appropriate mass-spectrometric method can be used to verify that the detected molecular species is consistent with Lys-Glu. The reference molecular weight for lysylglutamic acid is approximately 275.30 g/mol.
Where appropriate, additional analytical techniques can be used to examine composition or related impurities. Results should be interpreted according to the specification for the precise chemical form supplied, including any applicable salt or counter-ion.
Each batch should have a batch-specific Certificate of Analysis documenting the compound identity, purity, analytical method, testing date, and lot number.
The research material containing Vilon (Lys-Glu) should be stored according to the batch-specific conditions provided for the supplied material and documented in the applicable Certificate of Analysis. Storage should protect the material from moisture, light, contamination, and unnecessary temperature fluctuations, where applicable to the specified product form.
Handling should follow appropriate laboratory procedures to reduce the risk of contamination and maintain material integrity. Because storage conditions may vary according to the physical form, formulation, and batch. The validated documentation specific to the supplied material should take precedence over general storage guidance.
Vilon is usually described in the literature as a synthetic dipeptide made up of L-lysine and L-glutamic acid and is frequently represented as Lys-Glu (KE), being used as a well-defined short-peptide for research purposes.
Vilon is made up of only two amino acid residues and is therefore a dipeptide and not an oligopeptide or a protein; since it has no disulfide bonds, no glycosylation, and no complex tertiary structure, its molecular identity is mainly determined by the sequence of its Lys-Glu residues, its stereochemistry, and its molecular composition.
Work that has been published has looked at Vilon in relation to cellular signaling, gene expression, thymocyte, and chromatin-related research models. Since these studies are mainly experimental and preclinical, their results must be understood in the context of the particular laboratory systems employed.
Vilon has been investigated in mouse thymocyte models examining the sphingomyelin signal-transduction pathway. One published study measured sphingomyelinase activity and thymocyte responses following experimental exposure to Vilon, providing a biochemical model for studying short-peptide-associated signaling.
By no means has a single, well-characterized receptor or definite molecular target for Vilon been conclusively identified. Although studies have looked into gene-expression and signaling-related mechanisms, these still depend on the model and therefore should not be regarded as a full or universally established mechanism.
Vilon can be examined by means of complementary analytical techniques such as HPLC and mass spectrometry; HPLC is able to determine the chromatographic purity, and mass spectrometry can be used to confirm that the molecular species observed is in agreement with the expected Lys-Glu dipeptide.
Batch-specific verification helps establish that the supplied material matches the stated identity and purity specifications. Broad Payments also requires each product to have a batch-specific third-party Certificate of Analysis identifying the lot number, testing date, compound identity, purity, and analytical method.
Vilon has a distinct Lys-Glu sequence and corresponding molecular mass, so it can be differentiated from other dipeptides or short peptides using chromatographic retention behavior together with mass-spectrometric data. Where necessary, additional structural methods can be used to provide further confirmation of identity.
Vilon is a scientific and analytical research substance and is only for laboratory research use. It is not meant for human or animal ingestion or administration and is not offered for diagnostic, therapeutic, clinical, or veterinary use.
This page provides information for scientific and technical reference only. References to molecular interactions, gene expression or signaling pathways describe areas of laboratory investigation and should not be interpreted as evidence of clinical efficacy or therapeutic suitability.
